Navigation Links
Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
Date:10/19/2009

SAN FRANCISCO, Oct. 19 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

European Orphan Drug Designation encourages the development of products that demonstrate promise for the treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union. The designation criteria also specify that there is no other satisfactory therapy for that indication and that if JX-594 is shown to be effective in pivotal trials, it would represent a significant clinical benefit to HCC patients. Orphan Drug status for JX-594 entitles Jennerex to 10 year market exclusivity in Europe if the Market Authorization Application (MAA) is approved as well as potentially increasing reimbursement pricing. The designation also confers special benefits, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

"This designation is an important step in the development of a potential breakthrough treatment for this lethal disease," said David H. Kirn, M.D., President and Chief Executive Officer of Jennerex. "We look forward to working closely with the European regulatory authorities to complete the global development of JX-594 for the treatment of primary liver cancer."

About Hepatocellular Carcinoma

The treatment of advanced hepatocellular carcinoma represents a significant unmet medical need. HCC is responsible for about 90 percent of the primary malignant liver tumors in adults. Most cases of HCC are secondary to either a viral hepatic infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis). The usual outcome for patients is poor, because only 10 to 20 percent of hepatocellular carcinomas can be removed completely using surgery. If the cancer cannot be completely removed, the disease is usually deadly within three to six months.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com.

SOURCE Jennerex, Inc.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)...  Using Astute Medical,s NephroCheck Test ... kidney injury (AKI) after open-heart surgery and providing ... significantly improved outcomes by reducing the occurrence ... percent, according to a study published ... Medicine. Experience the interactive Multimedia ...
(Date:1/23/2017)... York , January 23, 2017 A ... Prenatal Testing Market was valued at US$0.53 bn in 2013 ... at a strong 17.50% CAGR between 2014 and 2022. The title ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 - ... Non-invasive prenatal ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... und 3B Medical ( Winter Haven, Florida ... Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den ... Verkauf ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren ... an 3B leisten, um das in Florida ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at the ... The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will feature ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the ... Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia ... 2012 and in less than a year was able to turn professional, participating in ...
(Date:1/23/2017)... ARLINGTON, VA (PRWEB) , ... ... ... Seafood Nutrition Partnership (SNP) has launched online education programs and resources at ... health and nutritional benefits of a seafood-rich diet. These resources have been ...
(Date:1/22/2017)... , ... January 22, 2017 , ... Zifam Pinnacle, an ... the world, recently met with big-name retail buyers at the January ECRM Trade Show ... efficacy and uses the utmost safety standards in all of its creations to help ...
(Date:1/21/2017)... ... 21, 2017 , ... "ProDOF is the perfect set of tools for video editors that want ... scene," said Christina Austin - CEO of Pixel Film Studios. , Video editors using ... illusion of a DSLR racking focus from one area into the next. ProDOF comes ...
Breaking Medicine News(10 mins):